Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab

Dermatology Practical & Conceptual, Год журнала: 2024, Номер unknown, С. e2024204 - e2024204

Опубликована: Июль 31, 2024

The advent of biotechnological drugs has significantly changed the management atopic dermatitis (AD) and approach to moderate-to-severe form this chronic relapsing disease.

Язык: Английский

---

Immunological Advancements In Hand Eczema Treatment: Progress With Small Molecules and Biologics

Current Treatment Options in Allergy, Год журнала: 2024, Номер unknown

Опубликована: Сен. 19, 2024

Язык: Английский

---

Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)

Current Medical Research and Opinion, Год журнала: 2024, Номер unknown, С. 1 - 19

Опубликована: Дек. 3, 2024

Objective To evaluate efficacy and safety of lebrikizumab combined with topical corticosteroids (TCS) in Japanese patients moderate-to-severe atopic dermatitis (AD).

Язык: Английский

---

T cells promote distinct transcriptional programs of cutaneous inflammatory disease in human skin structural cells

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Июль 31, 2024

Abstract T cells and structural coordinate appropriate inflammatory responses restoration of barrier integrity following insult. Dysfunctional cell activity precipitates tissue pathology that occurs alongside disease-associated alterations subsets, but the mechanisms by which promote these changes remain unclear. We show subsets circulating skin-resident CD4 + distinct transcriptional outcomes in human keratinocytes dermal fibroblasts correspond with divergent cytokine production. Using signatures, we identify cell-dependent associated skin disease, including a set h 17 cell-induced genes are enriched during psoriasis normalized anti-IL-17 therapy, gene module scleroderma-associated fibroblasts. Interrogating clinical data using cell-derived networks enables investigation immune-dependent contribution to disease heterogeneous patient response biologic therapy.

Язык: Английский

---

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis

BioDrugs, Год журнала: 2024, Номер 38(6), С. 821 - 830

Опубликована: Окт. 15, 2024

Eblasakimab, a first-in-class monoclonal antibody with unique mechanism to target the interleukin (IL)-13 receptor alpha 1 (IL-13Rα1), inhibits IL-4/IL-13 signaling in pathophysiology of atopic dermatitis (AD). This study investigates impact eblasakimab on type 2 inflammatory biomarkers patients moderate-to-severe AD.

Язык: Английский

---

The search for blood biomarkers useful in treating atopic dermatitis patients

Expert Review of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 4, 2024

Introduction Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well a course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try discover develop biomarkers useful for treating patients.

Язык: Английский

---

Tralokinumab Treatment of Atopic Dermatits Induces A Progressive Transcriptomic Response

Journal of Investigative Dermatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

---